Good morning :)
Place Order
Add to Watchlist

Lincoln Pharmaceuticals Ltd

LINCOLN Share Price

556.001.48% (+8.10)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹1,097 cr, stock is ranked 1,432

Stock is 3.51x as volatile as Nifty

LINCOLN Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹1,097 cr, stock is ranked 1,432

Stock is 3.51x as volatile as Nifty

LINCOLN Performance & Key Metrics

LINCOLN Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
13.331.850.33%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
37.436.450.80%

LINCOLN Analyst Ratings & Forecast

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

LINCOLN Company Profile

Lincoln Pharmaceuticals Limited (LPL) is engaged in the business of manufacturing, marketing and distribution of pharmaceutical products.

LINCOLN Similar Stocks (Peers)

Compare with peers Compare with peers 

LINCOLN Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
36.94
36.94
1Y Return
6.08%
6.08%
Buy Reco %
87.10
87.10
PE Ratio
22.73
22.73
1Y Return
2.19%
2.19%
Buy Reco %
73.33
73.33
PE Ratio
60.29
60.29
1Y Return
15.28%
15.28%
Buy Reco %
70.83
70.83
PE Ratio
55.89
55.89
1Y Return
25.50%
25.50%
Buy Reco %
81.25
81.25
PE Ratio
18.40
18.40
1Y Return
7.97%
7.97%
Buy Reco %
50.00
50.00
Compare with Peers

LINCOLN Sentiment Analysis

LINCOLN Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

LINCOLN Stock Summary · May 2024

The company is strategically expanding its market presence in the EU, Canada, and Australia, while maintaining a strong commitment to operational efficiency and regulatory compliance. Despite facing challenges such as increased debtor days and rising material costs, management remains optimistic about achieving a targeted annual growth rate of 15% to 18% and aims to reach INR 1,000 crores in revenue over the next three years. Investments in green energy and a focus on high-demand therapeutic areas like cardiology and diabetes underscore its commitment to sustainable growth. Additionally, the successful commercialization of the Cephalosporin plant positions the company to capitalize on rising antibiotic needs, further enhancing its revenue potential. Overall, the sentiment reflects a balanced approach to navigating operational challenges while pursuing ambitious growth objectives.

LINCOLN Stock Growth Drivers
LINCOLN Stock Growth Drivers
8
  • Market Expansion and International Presence

    The company has successfully expanded its operations into 60 countries and over 13-15 states in

  • Commitment to Quality and Compliance

    The company has consistently upgraded its products and manufacturing practices in line with WHO guidelines

LINCOLN Stock Challenges
LINCOLN Stock Challenges
5
  • Decline in Gross Margins

    The company has experienced a significant decline in gross margins, with a drop from 57%

  • Operating Margin Concerns

    Operating margins have shown a downward trend, decreasing from 17% in March 2022 to 15%

LINCOLN Forecast

LINCOLN Forecasts

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

LINCOLN

LINCOLN

Income

Balance Sheet

Cash Flow

LINCOLN Income Statement

LINCOLN Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 10.19%, vs industry avg of 10.04%

Constant Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share stayed at 0.16%

Lower than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 9.87%, vs industry avg of 19.67%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue362.99366.07371.78397.53429.85482.12532.78614.97645.71645.70
Raw Materialssubtract224.23195.49164.92191.33193.75232.15245.64284.04521.74521.73
Power & Fuel Costsubtract5.926.827.218.187.108.3310.2511.47
Employee Costsubtract37.5951.1551.9058.6563.2679.7293.16102.90
Selling & Administrative Expensessubtract36.7140.9644.2850.8851.0050.9054.4661.00
Operating & Other expensessubtract9.0313.8730.6011.9221.905.5417.6021.23
Depreciation/Amortizationsubtract5.516.116.687.337.568.099.1710.6212.9012.89
Interest & Other Itemssubtract6.665.414.002.021.561.452.031.461.881.89
Taxes & Other Itemssubtract9.2111.6213.4815.8021.4726.5827.5828.9326.8526.84
EPS15.4917.3224.3525.7131.1034.6336.3946.5941.1141.11
DPS1.201.501.501.501.501.501.501.801.801.80
Payout ratio0.080.090.060.060.050.040.040.040.040.04

LINCOLN Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2024FY 2024

Annual report

PDF
FY 2023FY 2023

Annual report

PDF
FY 2022FY 2022

Annual report

PDF
FY 2021FY 2021

Annual report

PDF
FY 2020FY 2020

Annual report

PDF
FY 2019FY 2019

Annual report

PDF
FY 2018FY 2018

Annual report

PDF
FY 2017FY 2017

Annual report

PDF

Investor Presentation

Aug 17PDF
FY 2016FY 2016

Annual report

PDF
FY 2015FY 2015

Annual report

PDF
 

LINCOLN Stock Peers

LINCOLN Past Performance & Peer Comparison

LINCOLN Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Lincoln Pharmaceuticals Ltd13.331.850.33%
Sun Pharmaceutical Industries Ltd36.945.570.95%
Cipla Ltd22.733.831.08%
Torrent Pharmaceuticals Ltd60.2915.180.94%

LINCOLN Stock Price Comparison

Compare LINCOLN with any stock or ETF
Compare LINCOLN with any stock or ETF
LINCOLN
Loading...

LINCOLN Holdings

LINCOLN Shareholdings

LINCOLN Promoter Holdings Trend

LINCOLN Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

LINCOLN Institutional Holdings Trend

LINCOLN Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

LINCOLN Shareholding Pattern

LINCOLN Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding49.78%0.00%0.00%5.00%45.22%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

LINCOLN Shareholding History

LINCOLN Shareholding History

Dec '23MarJunSepDec '24Mar3.23%3.93%3.95%5.19%5.16%5.00%

Mutual Funds Invested in LINCOLN

Mutual Funds Invested in LINCOLN

No mutual funds holding trends are available

Top 1 Mutual Funds holding Lincoln Pharmaceuticals Ltd


Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.0007%0.04%-0.00%99/109 (-5)

Compare 3-month MF holding change on Screener

LINCOLN Insider Trades & Bulk Stock Deals

LINCOLN Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing LINCOLN stock

smallcases containing LINCOLN stock

Looks like this stock is not in any smallcase yet.

LINCOLN Events

LINCOLN Events

LINCOLN Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

LINCOLN has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.33%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.29 every year

Dividends

Corp. Actions

Announcements

Legal Orders

LINCOLN Dividend Trend

No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year

LINCOLN has increased or maintained dividend levels over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.33%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.29 every year

LINCOLN Upcoming Dividends

LINCOLN Upcoming Dividends

No upcoming dividends are available

LINCOLN Past Dividends

LINCOLN Past Dividends

Cash Dividend

Ex DateEx DateSep 13, 2024

Final
Final | Div/Share: ₹1.80

Dividend/Share

1.80

Ex DateEx Date

Sep 13, 2024

Cash Dividend

Ex DateEx DateSep 15, 2023

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Sep 15, 2023

Cash Dividend

Ex DateEx DateSep 15, 2022

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Sep 15, 2022

Cash Dividend

Ex DateEx DateSep 16, 2021

Final
Final | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Sep 16, 2021

Cash Dividend

Ex DateEx DateMar 5, 2020

Interim
Interim | Div/Share: ₹1.50

Dividend/Share

1.50

Ex DateEx Date

Mar 5, 2020

LINCOLN Stock News & Opinions

LINCOLN Stock News & Opinions

Corporate
Board of Lincoln Pharmaceuticals recommends final dividend

Lincoln Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 22 May 2025, inter alia, have recommended the final dividend of Rs 1.8 per equity Share (i.e. 18%) , subject to the approval of the shareholders.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Lincoln Pharmaceuticals consolidated net profit declines 37.74% in the March 2025 quarter

Net profit of Lincoln Pharmaceuticals declined 37.74% to Rs 11.58 crore in the quarter ended March 2025 as against Rs 18.60 crore during the previous quarter ended March 2024. Sales rose 18.03% to Rs 168.18 crore in the quarter ended March 2025 as against Rs 142.49 crore during the previous quarter ended March 2024. For the full year,net profit declined 11.74% to Rs 82.35 crore in the year ended March 2025 as against Rs 93.30 crore during the previous year ended March 2024. Sales rose 7.35% to Rs 623.23 crore in the year ended March 2025 as against Rs 580.55 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales168.18142.49 18 623.23580.55 7 OPM %15.8912.90 -16.2817.21 - PBDT19.4724.90 -22 122.09132.87 -8 PBT16.2522.22 -27 109.19122.24 -11 NP11.5818.60 -38 82.3593.30 -12 Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Lincoln Pharmaceuticals to declare Quarterly Results

Lincoln Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 22 May 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Lincoln Pharmaceuticals consolidated net profit declines 25.93% in the December 2024 quarter

Net profit of Lincoln Pharmaceuticals declined 25.93% to Rs 20.77 crore in the quarter ended December 2024 as against Rs 28.04 crore during the previous quarter ended December 2023. Sales rose 0.07% to Rs 146.55 crore in the quarter ended December 2024 as against Rs 146.45 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales146.55146.45 0 OPM %16.1420.25 - PBDT31.9140.52 -21 PBT28.6837.71 -24 NP20.7728.04 -26 Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Lincoln Pharmaceuticals to announce Quarterly Result

Lincoln Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 February 2025.Powered by Capital Market - Live

5 months agoCapital Market - Live
Earnings
Lincoln Pharmaceuticals consolidated net profit declines 4.77% in the September 2024 quarter

Net profit of Lincoln Pharmaceuticals declined 4.77% to Rs 26.33 crore in the quarter ended September 2024 as against Rs 27.65 crore during the previous quarter ended September 2023. Sales rose 3.35% to Rs 161.21 crore in the quarter ended September 2024 as against Rs 155.99 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales161.21155.99 3 OPM %17.6019.97 - PBDT38.0139.45 -4 PBT34.7836.87 -6 NP26.3327.65 -5 Powered by Capital Market - Live

7 months agoCapital Market - Live
Corporate
Lincoln Pharmaceuticals announces board meeting date

Lincoln Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live

8 months agoCapital Market - Live
Corporate
Lincoln Pharmaceuticals AGM scheduled

Lincoln Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

10 months agoCapital Market - Live
Corporate
Lincoln Pharmaceuticals to conduct AGM

Lincoln Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

10 months agoCapital Market - Live
Earnings
Lincoln Pharmaceuticals consolidated net profit rises 24.51% in the June 2024 quarter

Net profit of Lincoln Pharmaceuticals rose 24.51% to Rs 23.67 crore in the quarter ended June 2024 as against Rs 19.01 crore during the previous quarter ended June 2023. Sales rose 8.60% to Rs 147.28 crore in the quarter ended June 2024 as against Rs 135.62 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales147.28135.62 9 OPM %15.4315.28 - PBDT32.7027.99 17 PBT29.4825.45 16 NP23.6719.01 25 Powered by Capital Market - Live

11 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Lincoln Pharmaceuticals Ltd (LINCOLN) today?

    The share price of LINCOLN as on 15th July 2025 is ₹556. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Lincoln Pharmaceuticals Ltd (LINCOLN) share?

    The past returns of Lincoln Pharmaceuticals Ltd (LINCOLN) share are
    • Past 1 week: -2.75%
    • Past 1 month: -6.02%
    • Past 3 months: -0.85%
    • Past 6 months: -30.72%
    • Past 1 year: -16.48%
    • Past 3 years: 76.23%
    • Past 5 years: 185.74%

  3. What are the peers or stocks similar to Lincoln Pharmaceuticals Ltd (LINCOLN)?
  4. What is the dividend yield % of Lincoln Pharmaceuticals Ltd (LINCOLN) share?

    The current dividend yield of Lincoln Pharmaceuticals Ltd (LINCOLN) is 0.33.

  5. What is the market cap of Lincoln Pharmaceuticals Ltd (LINCOLN) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lincoln Pharmaceuticals Ltd (LINCOLN) is ₹1097.43 Cr as of 15th July 2025.

  6. What is the 52 week high and low of Lincoln Pharmaceuticals Ltd (LINCOLN) share?

    The 52-week high of Lincoln Pharmaceuticals Ltd (LINCOLN) is ₹979.50 and the 52-week low is ₹499.

  7. What is the PE and PB ratio of Lincoln Pharmaceuticals Ltd (LINCOLN) stock?

    The P/E (price-to-earnings) ratio of Lincoln Pharmaceuticals Ltd (LINCOLN) is 13.33. The P/B (price-to-book) ratio is 1.85.

  8. Which sector does Lincoln Pharmaceuticals Ltd (LINCOLN) belong to?

    Lincoln Pharmaceuticals Ltd (LINCOLN) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Lincoln Pharmaceuticals Ltd (LINCOLN) shares?

    You can directly buy Lincoln Pharmaceuticals Ltd (LINCOLN) shares on Tickertape. Simply sign up, connect your demat account and place your order.